| 1 | Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial. (Lee JM, Miller A, Rose PG, AlHilli M, Washington C, John VS, Shah CA, Matsuo K, Siedel J, Miller DS, Hopp EE, O'Shea A, Chan JK, Bradford LS, Morse CB, Nagel CI, Rodabaugh KJ, Kohn EC, Moore KN, Liu JF) Clin Cancer Res 2025 Jun 13;31(12):2370-2378 4 Citations |
| 1 | Targeting NUPR1-dependent stress granules formation to induce synthetic lethality in KrasG12D-driven tumors. (Santofimia-Castaño P, Fraunhoffer N, Liu X, Bessone IF, di Magliano MP, Audebert S, Camoin L, Estaras M, Brenière M, Modesti M, Lomberk G, Urrutia R, Soubeyran P, Neira JL, Iovanna J) EMBO Mol Med 2024 Mar;16(3):475-505 19 Citations |
| 1 | Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. (Schweizer MT, Gulati R, Yezefski T, Cheng HH, Mostaghel E, Haffner MC, Patel RA, De Sarkar N, Ha G, Dumpit R, Woo B, Lin A, Panlasigui P, McDonald N, Lai M, Nega K, Hammond J, Grivas P, Hsieh A, Montgomery B, Nelson PS, Yu EY) Prostate Cancer Prostatic Dis 2023 Mar;26(1):194-200 19 Citations |
| 1 | NUPR1 protects against hyperPARylation-dependent cell death. (Santofimia-Castaño P, Huang C, Liu X, Xia Y, Audebert S, Camoin L, Peng L, Lomberk G, Urrutia R, Soubeyran P, Neira JL, Iovanna J) Commun Biol 2022 Jul 22;5(1):732 17 Citations |
| 1 | A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. (Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, Wunder F, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, Rubin E, Young B, Onn A, Leyland-Jones B, Schilsky RL, Lazar V, Felip E, Kurzrock R) Cancer Med 2022 Jul;11(14):2790-2800 22 Citations |
| 1 | Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. (Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P) Lancet Oncol 2021 Dec;22(12):1721-1731 329 Citations |
| 1 | Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. (Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P) Gynecol Oncol 2021 Oct;163(1):41-49 34 Citations |
| 1 | Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. (Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P) Lancet Oncol 2021 May;22(5):632-642 51 Citations |
| 2 | ZZW-115-dependent inhibition of NUPR1 nuclear translocation sensitizes cancer cells to genotoxic agents. (Lan W, Santofimia-Castaño P, Swayden M, Xia Y, Zhou Z, Audebert S, Camoin L, Huang C, Peng L, Jiménez-Alesanco A, Velázquez-Campoy A, Abián O, Lomberk G, Urrutia R, Rizzuti B, Geli V, Soubeyran P, Neira JL, Iovanna J) JCI Insight 2020 Sep 17;5(18) 40 Citations |
| 1 | Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. (DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN) J Clin Oncol 2020 Oct 20;38(30):3528-3537 90 Citations |
| 1 | D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine. (Shen Y, McCorvy JD, Martini ML, Rodriguiz RM, Pogorelov VM, Ward KM, Wetsel WC, Liu J, Roth BL, Jin J) J Med Chem 2019 May 09;62(9):4755-4771 19 Citations |
| 1 | GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. (Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK) Mol Cancer Ther 2019 May;18(5):969-979 17 Citations |
| 1 | Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P) N Engl J Med 2018 Dec 27;379(26):2495-2505 2395 Citations |
| 1 | The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. (Branchford BR, Stalker TJ, Law L, Acevedo G, Sather S, Brzezinski C, Wilson KM, Minson K, Lee-Sherick AB, Davizon-Castillo P, Ng C, Zhang W, Neeves KB, Lentz SR, Wang X, Frye SV, Shelton Earp H 3rd, DeRyckere D, Brass LF, Graham DK, Di Paola JA) J Thromb Haemost 2018 Feb;16(2):352-363 27 Citations |
| 1 | Dolutegravir-induced paresthesias. (Fulco PP, Gomes DC, Bozymski KM) AIDS 2017 Jul 17;31(11):1645-1646 1 Citation |
| 1 | Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). (Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, Stratford A, Klein LM, McCorvy JD, Nichols DE, Halberstadt AL) Drug Test Anal 2018 Feb;10(2):310-322 51 Citations |
| 1 | Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. (Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman SM, Kurzrock R) Clin Cancer Res 2017 Aug 15;23(16):4716-4723 119 Citations |
| 1 | In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase. (Bassetto M, Leyssen P, Neyts J, Yerukhimovich MM, Frick DN, Courtney-Smith M, Brancale A) Eur J Med Chem 2017 Jan 05;125:1115-1131 21 Citations |
| 1 | Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. (Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD) Oncotarget 2016 Apr 12;7(15):20825-39 8 Citations |
| 1 | Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. (Falchook GS, Bastida CC, Kurzrock R) Semin Oncol 2015 Dec;42(6):832-48 100 Citations |
| 1 | A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. (Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM) BMC Cancer 2014 Aug 02;14:561 15 Citations |
| 1 | Bidirectional effects of inhibiting or potentiating NMDA receptors on extinction after cocaine self-administration in rats. (Hafenbreidel M, Rafa Todd C, Twining RC, Tuscher JJ, Mueller D) Psychopharmacology (Berl) 2014 Dec;231(24):4585-94 17 Citations |
| 1 | Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. (Liu ZJ, Hoffmeister KM, Hu Z, Mager DE, Ait-Oudhia S, Debrincat MA, Pleines I, Josefsson EC, Kile BT, Italiano J Jr, Ramsey H, Grozovsky R, Veng-Pedersen P, Chavda C, Sola-Visner M) Blood 2014 May 29;123(22):3381-9 66 Citations |
| 1 | Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia. (Anzalone CL, Cohen PR, Kurzrock R, Cortes JE) Dermatol Online J 2014 Jan 15;20(1):21242 6 Citations |
| 1 | Regulation of ferroptotic cancer cell death by GPX4. (Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR) Cell 2014 Jan 16;156(1-2):317-331 6498 Citations |
| 1 | Imatinib tackles lymphoma via the PDGFRβ+ pericyte. (Chute JP, Himburg HA) Blood 2013 Jun 27;121(26):5107-8 9 Citations |
| 1 | It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. (Westin JR, Kurzrock R) Mol Cancer Ther 2012 Dec;11(12):2549-55 53 Citations |
| 1 | Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome. (Pardanani A, D'Souza A, Knudson RA, Hanson CA, Ketterling RP, Tefferi A) Leukemia 2012 Nov;26(11):2439-41 54 Citations |
| 1 | Chronic myelogenous leukemia for primary care physicians. (Torgerson SR, Haddad RY, Atallah E) Dis Mon 2012 Apr;58(4):168-76 10 Citations |
| 1 | Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. (Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, Akpek G, Aljurf M, Cahn JY, Cairo M, Chen YB, Cooper B, Deol A, Giralt S, Gupta V, Khoury HJ, Kohrt H, Lazarus HM, Lewis I, Olsson R, Pidala J, Savani BN, Seftel M, Socié G, Tallman M, Ustun C, Vij R, Vindeløv L, Weisdorf D) Blood 2012 Apr 26;119(17):4083-90 49 Citations |
| 1 | Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. (Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, Camitta BM, Winick NJ, Druker BJ, Schultz KR) Br J Haematol 2012 May;157(4):507-10 39 Citations |
| 3 | Damage to mitochondrial complex I during cardiac ischemia reperfusion injury is reduced indirectly by anti-anginal drug ranolazine. (Gadicherla AK, Stowe DF, Antholine WE, Yang M, Camara AK) Biochim Biophys Acta 2012 Mar;1817(3):419-29 85 Citations |
| 1 | Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a-/- mutants. (Sapetto-Rebow B, McLoughlin SC, O'Shea LC, O'Leary O, Willer JR, Alvarez Y, Collery R, O'Sullivan J, Van Eeden F, Hensey C, Kennedy BN) BMC Dev Biol 2011 Nov 23;11:71 18 Citations |
| 2 | Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. (Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, Gupta V, Rizzieri DA, George B, Keating A, Gale RP, Marks DI, McCarthy PL, Woolfrey A, Szer J, Giralt SA, Maziarz RT, Cortes J, Horowitz MM, Lee SJ) Bone Marrow Transplant 2012 Jun;47(6):810-6 83 Citations |
| 2 | Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts. (Aldakkak M, Camara AK, Heisner JS, Yang M, Stowe DF) Pharmacol Res 2011 Oct;64(4):381-92 105 Citations |
| 1 | Analogues of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with added polar functionality and reduced lipophilicity for potential use as positron emission tomography radiotracers. (Abate C, Niso M, Lacivita E, Mosier PD, Toscano A, Perrone R) J Med Chem 2011 Feb 24;54(4):1022-32 53 Citations |
| 1 | Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options. (Schultz KR, Prestidge T, Camitta B) Expert Rev Hematol 2010 Dec;3(6):731-42 17 Citations |
| 1 | Neuronal bursting properties in focal and parafocal regions in pediatric neocortical epilepsy stratified by histology. (Marcuccilli CJ, Tryba AK, van Drongelen W, Koch H, Viemari JC, Peña-Ortega F, Doren EL, Pytel P, Chevalier M, Mrejeru A, Kohrman MH, Lasky RE, Lew SM, Frim DM, Ramirez JM) J Clin Neurophysiol 2010 Dec;27(6):387-97 |
| 1 | Response of histiocytoses to imatinib mesylate: fire to ashes. (Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R) J Clin Oncol 2010 Nov 01;28(31):e633-6 77 Citations |
| 1 | Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. (Bardsley MR, Horváth VJ, Asuzu DT, Lorincz A, Redelman D, Hayashi Y, Popko LN, Young DL, Lomberk GA, Urrutia RA, Farrugia G, Rubin BP, Ordog T) Gastroenterology 2010 Sep;139(3):942-52 104 Citations |
| 1 | Bone marrow or peripheral blood. (Eapen M) Biol Blood Marrow Transplant 2010 Jun;16(6):868-9 |
| 1 | Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. (Bilgi N, Bell K, Ananthakrishnan AN, Atallah E) Ann Pharmacother 2010 May;44(5):926-8 111 Citations |
| 1 | Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet) J Clin Oncol 2009 Dec 10;27(35):6041-51 1164 Citations |
| 1 | Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. (Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Wang C, Davies SM, Gaynon PS, Trigg M, Rutledge R, Burden L, Jorstad D, Carroll A, Heerema NA, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B) J Clin Oncol 2009 Nov 01;27(31):5175-81 605 Citations |
| 1 | Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). (Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR) Pediatr Blood Cancer 2009 Dec 15;53(7):1289-94 24 Citations |
| 1 | Resolution of rheumatoid arthritis symptoms with imatinib mesylate. (Vernon MR, Pearson L, Atallah E) J Clin Rheumatol 2009 Aug;15(5):267 10 Citations |
| 1 | Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. (Oravecz-Wilson KI, Philips ST, Yilmaz OH, Ames HM, Li L, Crawford BD, Gauvin AM, Lucas PC, Sitwala K, Downing JR, Morrison SJ, Ross TS) Cancer Cell 2009 Aug 04;16(2):137-48 63 Citations |
| 1 | Practical considerations for the management of patients in the tyrosine kinase inhibitor era. (O'Dwyer M, Atallah E) Semin Hematol 2009 Apr;46(2 Suppl 3):S16-21 12 Citations |
| 1 | The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. (Burke MJ, Willert J, Desai S, Kadota R) Pediatr Blood Cancer 2009 Dec;53(6):992-5 10 Citations |
| 2 | Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. (Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah E) Leuk Res 2009 Aug;33(8):1144-6 34 Citations |
| 1 | Molecular imaging of Bcr-Abl phosphokinase in a xenograft model. (Wu JY, Yang DJ, Angelo LS, Kohanim S, Kurzrock R) Mol Cancer Ther 2009 Mar;8(3):703-10 5 Citations |
| 1 | Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. (Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Aug;44(3):169-74 12 Citations |
| 1 | Effects of sildenafil on nigrostriatal dopamine neurons in a murine model of Parkinson's disease. (Janis KL, Brennan RT, Drolet RE, Behrouz B, Kaufman SK, Lookingland KJ, Goudreau JL) J Alzheimers Dis 2008 Sep;15(1):97-107 8 Citations |
| 1 | Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. (Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Jan;43(2):107-13 47 Citations |
| 2 | Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. (Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT) Blood 2008 Oct 15;112(8):3500-7 120 Citations |
| 1 | What's new in clinical pharmacology and therapeutics. (Chawla PS, Kochar MS) WMJ 2008 Apr;107(2):76-83 |
| 3 | Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma. (Ahmed MS, Kroft SH, Davis NB, King DM, Cheng YC) Leuk Res 2008 Sep;32(9):1476-9 6 Citations |
| 1 | Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. (Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W) Leuk Lymphoma 2008 Mar;49(3):531-7 8 Citations |
| 2 | Diabetes abolishes sildenafil-induced cGMP-dependent protein kinase-I expression and cardioprotection. (Jamnicki-Abegg M, Weihrauch D, Chiari PC, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR) J Cardiovasc Pharmacol 2007 Dec;50(6):670-6 16 Citations |
| 1 | Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. (Park ES, Shaughnessy JD Jr, Gupta S, Wang H, Lee JS, Woo HG, Zhan F, Owens JD Jr, Potter M, Janz S, Mushinski JF) BMC Genomics 2007 Aug 31;8:302 19 Citations |
| 1 | Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo. (Hacker TA, Griffin MO, Guttormsen B, Stoker S, Wolff MR) J Invasive Cardiol 2007 Jun;19(6):269-74 14 Citations |
| 1 | Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. (Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL, Sobocinski KA, Horowitz MM, Chronic Leukemia Working Committee, Center for International Blood and Marrow Transplant Research) Br J Haematol 2007 Jun;137(5):461-7 72 Citations |
| 1 | Congestive heart failure is a rare event in patients receiving imatinib therapy. (Atallah E, Durand JB, Kantarjian H, Cortes J) Blood 2007 Aug 15;110(4):1233-7 220 Citations |
| 1 | Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. (Atallah E, Kantarjian H, Cortes J) Clin Lymphoma Myeloma 2007 Mar;7 Suppl 3:S105-12 26 Citations |
| 1 | Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. (Atallah E, Cortes J) Curr Opin Hematol 2007 Mar;14(2):138-44 3 Citations |
| 1 | Serotonin 5-HT1A receptor stimulates c-Jun N-terminal kinase and induces apoptosis in Chinese hamster ovary fibroblasts. (Turner JH, Garnovskaya MN, Raymond JR) Biochim Biophys Acta 2007 Mar;1773(3):391-9 26 Citations |
| 1 | In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. (Atallah E, Kantarjian H, Cortes J) Nat Med 2007 Jan;13(1):14; author reply 15-6 39 Citations |
| 1 | Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. (Kurzrock R, Talpaz M, Li L, Estrov Z) Leuk Lymphoma 2006 Aug;47(8):1651-64 2 Citations |
| 1 | What's new in clinical pharmacology and therapeutics. (Chawla PS, Kochar MS) WMJ 2006 May;105(3):24-9 12 Citations |
| 1 | Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet) Blood 2006 Sep 15;108(6):1809-20 1148 Citations |
| 1 | Torsades de pointes associated with ziprasidone. (Heinrich TW, Biblo LA, Schneider J) Psychosomatics 2006;47(3):264-8 60 Citations |
| 1 | Effects of sildenafil on myocardial blood flow in humans with ischemic heart disease. (Tawakol A, Aziz K, Migrino R, Watkowska J, Zusman R, Alpert NM, Fischman AJ, Gewirtz H) Coron Artery Dis 2005 Nov;16(7):443-9 17 Citations |
| 1 | Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. (Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ) Clin Cancer Res 2003 Dec 15;9(17):6534-44 154 Citations |
| 1 | Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. (Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M) Ann Intern Med 2003 May 20;138(10):819-30 285 Citations |
| 2 | 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. (Shang T, Uihlein AV, Van Asten J, Kalyanaraman B, Hillard CJ) J Neurochem 2003 Apr;85(2):358-67 74 Citations |
| 1 | Delta opioid agonists and volatile anesthetics facilitate cardioprotection via potentiation of K(ATP) channel opening. (Patel HH, Ludwig LM, Fryer RM, Hsu AK, Warltier DC, Gross GJ) FASEB J 2002 Sep;16(11):1468-70 55 Citations |
| 1 | Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. (Atallah E, Talpaz M, O'brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H) Cancer 2002 Jun 01;94(11):2996-9 19 Citations |
| 1 | Chronic myelogenous leukemia in chronic phase. (Kurzrock R, Kantarjian H, Talpaz M) Curr Treat Options Oncol 2001 Jun;2(3):245-52 7 Citations |
| 1 | What is causing your patient's sexual dysfunction? Uncovering a connection with hypertension and antihypertensive therapy. (Kochar MS, Mazur LI, Patel A) Postgrad Med 1999 Aug;106(2):149-52, 155-7 22 Citations |
| 1 | Expression of Ca2+/calmodulin-dependent protein kinase types II and IV, and reduced DNA synthesis due to the Ca2+/calmodulin-dependent protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenyl piperazine) in small cell lung carcinoma. (Williams CL, Phelps SH, Porter RA) Biochem Pharmacol 1996 Mar 08;51(5):707-15 44 Citations |
| 1 | Inhibition of voltage-gated Ca2+ channel activity in small cell lung carcinoma by the Ca2+/calmodulin-dependent protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperaz ine) . (Williams CL, Porter RA, Phelps SH) Biochem Pharmacol 1995 Dec 22;50(12):1979-85 14 Citations |
| 1 | Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism. (Quarles LD, Hartle JE 2nd, Middleton JP, Zhang J, Arthur JM, Raymond JR) J Cell Biochem 1994 Sep;56(1):106-17 93 Citations |
| 1 | Protein kinase C induces phosphorylation and desensitization of the human 5-HT1A receptor. (Raymond JR) J Biol Chem 1991 Aug 05;266(22):14747-53 111 Citations |
| 1 | Cell alkalinization is not necessary and increased sodium influx is not sufficient for stimulated superoxide production. (Molski TF, Ford C, Weisman SJ, Sha'afi RI) FEBS Lett 1986 Jul 28;203(2):267-72 18 Citations |
| 1 | Calcium channel blockers in migraine. (Solomon GD) Lancet 1982 Jul 17;2(8290):162 8 Citations |
